Use of Recombinant Human Bone Morphogenetic Protein-2 at the C1-C2 Lateral Articulation without Posterior Structural Bone Graft in Posterior Atlantoaxial Fusion in Adult Patients

Wataru Ishida, Seba Ramhmdani, Yuanxuan Xia, Thomas A. Kosztowski, Risheng Xu, John Choi, Rafael De la Garza Ramos, Benjamin D. Elder, Nicholas Theodore, Ziya L. Gokaslan, Daniel Sciubba, Timothy F Witham, Ali Bydon, Jean Paul Wolinsky, Sheng-fu Lo

Research output: Contribution to journalArticle

Abstract

Background: Posterior atlantoaxial fusion is an important armamentarium for neurosurgeons to treat several pathologies involving the craniovertebral junction. Although the potential advantages of recombinant human bone morphogenetic protein-2 (rhBMP-2) are well documented in the lumbar spine, its indication for C1-C2 fusion has not been well characterized. In our institution, we apply rhBMP-2 to the C1-C2 joint either alone or with hydroxyapatite, locally harvested autograft chips, and/or morselized allogenic bone graft for selected cases—without conventional posterior structural bone graft. We report the clinical outcomes of the surgical technique to elucidate its feasibility. Methods: We performed a single-center, retrospective review of data from 2008 to 2016 and identified 69 patients who had undergone posterior atlantoaxial fusion with rhBMP-2. The clinical records of these patients were reviewed, and the baseline characteristics, operative data, and postoperative complications were collected and statistically analyzed. Results: The average age of the 69 patients was 60.8 ± 4.5 years, and 55.1% were women. With an average follow-up period of 21.1 ± 4.2 months, the C1-C2 fusion rate was 94.3% (65 of 69), and the average time to fusion was 11.4 ± 2.6 months (range, 5–23). The overall reoperation rate was 10.1% (7 of 69), with instrumentation failure in 7 patients (10.1%), adjacent segment disease in 2 (2.9%), and postoperative dysphagia and dyspnea in 2 patients (2.9%). No ectopic bone formation or soft tissue edema developed. Conclusions: Although retrospective and from a single center, our study has shown that rhBMP-2 usage at the C1-C2 joint without posterior structural bone grafting is a safe and reasonable surgical option.

Original languageEnglish (US)
JournalWorld Neurosurgery
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Transplants
Bone and Bones
Joints
Bone Transplantation
Autografts
Durapatite
Deglutition Disorders
Reoperation
Osteogenesis
Dyspnea
Edema
Spine
recombinant human bone morphogenetic protein-2
Atlanto-Axial Fusion
Pathology

Keywords

  • Atlantoaxial fusion
  • C1-C2 fusion
  • Pseudoarthrosis
  • rhBMP-2

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Use of Recombinant Human Bone Morphogenetic Protein-2 at the C1-C2 Lateral Articulation without Posterior Structural Bone Graft in Posterior Atlantoaxial Fusion in Adult Patients. / Ishida, Wataru; Ramhmdani, Seba; Xia, Yuanxuan; Kosztowski, Thomas A.; Xu, Risheng; Choi, John; De la Garza Ramos, Rafael; Elder, Benjamin D.; Theodore, Nicholas; Gokaslan, Ziya L.; Sciubba, Daniel; Witham, Timothy F; Bydon, Ali; Wolinsky, Jean Paul; Lo, Sheng-fu.

In: World Neurosurgery, 01.01.2018.

Research output: Contribution to journalArticle

Ishida, Wataru ; Ramhmdani, Seba ; Xia, Yuanxuan ; Kosztowski, Thomas A. ; Xu, Risheng ; Choi, John ; De la Garza Ramos, Rafael ; Elder, Benjamin D. ; Theodore, Nicholas ; Gokaslan, Ziya L. ; Sciubba, Daniel ; Witham, Timothy F ; Bydon, Ali ; Wolinsky, Jean Paul ; Lo, Sheng-fu. / Use of Recombinant Human Bone Morphogenetic Protein-2 at the C1-C2 Lateral Articulation without Posterior Structural Bone Graft in Posterior Atlantoaxial Fusion in Adult Patients. In: World Neurosurgery. 2018.
@article{098dc1f544b7488192b4235f63281fe4,
title = "Use of Recombinant Human Bone Morphogenetic Protein-2 at the C1-C2 Lateral Articulation without Posterior Structural Bone Graft in Posterior Atlantoaxial Fusion in Adult Patients",
abstract = "Background: Posterior atlantoaxial fusion is an important armamentarium for neurosurgeons to treat several pathologies involving the craniovertebral junction. Although the potential advantages of recombinant human bone morphogenetic protein-2 (rhBMP-2) are well documented in the lumbar spine, its indication for C1-C2 fusion has not been well characterized. In our institution, we apply rhBMP-2 to the C1-C2 joint either alone or with hydroxyapatite, locally harvested autograft chips, and/or morselized allogenic bone graft for selected cases—without conventional posterior structural bone graft. We report the clinical outcomes of the surgical technique to elucidate its feasibility. Methods: We performed a single-center, retrospective review of data from 2008 to 2016 and identified 69 patients who had undergone posterior atlantoaxial fusion with rhBMP-2. The clinical records of these patients were reviewed, and the baseline characteristics, operative data, and postoperative complications were collected and statistically analyzed. Results: The average age of the 69 patients was 60.8 ± 4.5 years, and 55.1{\%} were women. With an average follow-up period of 21.1 ± 4.2 months, the C1-C2 fusion rate was 94.3{\%} (65 of 69), and the average time to fusion was 11.4 ± 2.6 months (range, 5–23). The overall reoperation rate was 10.1{\%} (7 of 69), with instrumentation failure in 7 patients (10.1{\%}), adjacent segment disease in 2 (2.9{\%}), and postoperative dysphagia and dyspnea in 2 patients (2.9{\%}). No ectopic bone formation or soft tissue edema developed. Conclusions: Although retrospective and from a single center, our study has shown that rhBMP-2 usage at the C1-C2 joint without posterior structural bone grafting is a safe and reasonable surgical option.",
keywords = "Atlantoaxial fusion, C1-C2 fusion, Pseudoarthrosis, rhBMP-2",
author = "Wataru Ishida and Seba Ramhmdani and Yuanxuan Xia and Kosztowski, {Thomas A.} and Risheng Xu and John Choi and {De la Garza Ramos}, Rafael and Elder, {Benjamin D.} and Nicholas Theodore and Gokaslan, {Ziya L.} and Daniel Sciubba and Witham, {Timothy F} and Ali Bydon and Wolinsky, {Jean Paul} and Sheng-fu Lo",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.wneu.2018.11.037",
language = "English (US)",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Use of Recombinant Human Bone Morphogenetic Protein-2 at the C1-C2 Lateral Articulation without Posterior Structural Bone Graft in Posterior Atlantoaxial Fusion in Adult Patients

AU - Ishida, Wataru

AU - Ramhmdani, Seba

AU - Xia, Yuanxuan

AU - Kosztowski, Thomas A.

AU - Xu, Risheng

AU - Choi, John

AU - De la Garza Ramos, Rafael

AU - Elder, Benjamin D.

AU - Theodore, Nicholas

AU - Gokaslan, Ziya L.

AU - Sciubba, Daniel

AU - Witham, Timothy F

AU - Bydon, Ali

AU - Wolinsky, Jean Paul

AU - Lo, Sheng-fu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Posterior atlantoaxial fusion is an important armamentarium for neurosurgeons to treat several pathologies involving the craniovertebral junction. Although the potential advantages of recombinant human bone morphogenetic protein-2 (rhBMP-2) are well documented in the lumbar spine, its indication for C1-C2 fusion has not been well characterized. In our institution, we apply rhBMP-2 to the C1-C2 joint either alone or with hydroxyapatite, locally harvested autograft chips, and/or morselized allogenic bone graft for selected cases—without conventional posterior structural bone graft. We report the clinical outcomes of the surgical technique to elucidate its feasibility. Methods: We performed a single-center, retrospective review of data from 2008 to 2016 and identified 69 patients who had undergone posterior atlantoaxial fusion with rhBMP-2. The clinical records of these patients were reviewed, and the baseline characteristics, operative data, and postoperative complications were collected and statistically analyzed. Results: The average age of the 69 patients was 60.8 ± 4.5 years, and 55.1% were women. With an average follow-up period of 21.1 ± 4.2 months, the C1-C2 fusion rate was 94.3% (65 of 69), and the average time to fusion was 11.4 ± 2.6 months (range, 5–23). The overall reoperation rate was 10.1% (7 of 69), with instrumentation failure in 7 patients (10.1%), adjacent segment disease in 2 (2.9%), and postoperative dysphagia and dyspnea in 2 patients (2.9%). No ectopic bone formation or soft tissue edema developed. Conclusions: Although retrospective and from a single center, our study has shown that rhBMP-2 usage at the C1-C2 joint without posterior structural bone grafting is a safe and reasonable surgical option.

AB - Background: Posterior atlantoaxial fusion is an important armamentarium for neurosurgeons to treat several pathologies involving the craniovertebral junction. Although the potential advantages of recombinant human bone morphogenetic protein-2 (rhBMP-2) are well documented in the lumbar spine, its indication for C1-C2 fusion has not been well characterized. In our institution, we apply rhBMP-2 to the C1-C2 joint either alone or with hydroxyapatite, locally harvested autograft chips, and/or morselized allogenic bone graft for selected cases—without conventional posterior structural bone graft. We report the clinical outcomes of the surgical technique to elucidate its feasibility. Methods: We performed a single-center, retrospective review of data from 2008 to 2016 and identified 69 patients who had undergone posterior atlantoaxial fusion with rhBMP-2. The clinical records of these patients were reviewed, and the baseline characteristics, operative data, and postoperative complications were collected and statistically analyzed. Results: The average age of the 69 patients was 60.8 ± 4.5 years, and 55.1% were women. With an average follow-up period of 21.1 ± 4.2 months, the C1-C2 fusion rate was 94.3% (65 of 69), and the average time to fusion was 11.4 ± 2.6 months (range, 5–23). The overall reoperation rate was 10.1% (7 of 69), with instrumentation failure in 7 patients (10.1%), adjacent segment disease in 2 (2.9%), and postoperative dysphagia and dyspnea in 2 patients (2.9%). No ectopic bone formation or soft tissue edema developed. Conclusions: Although retrospective and from a single center, our study has shown that rhBMP-2 usage at the C1-C2 joint without posterior structural bone grafting is a safe and reasonable surgical option.

KW - Atlantoaxial fusion

KW - C1-C2 fusion

KW - Pseudoarthrosis

KW - rhBMP-2

UR - http://www.scopus.com/inward/record.url?scp=85058680642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058680642&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2018.11.037

DO - 10.1016/j.wneu.2018.11.037

M3 - Article

C2 - 30448576

AN - SCOPUS:85058680642

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -